Percutaneous Management of Thrombosed Dialysis Access Grafts

This article reviews current concepts in the percutaneous management of thrombosed polytetrafluoroethylene (PTFE) dialysis access grafts. The maintenance of dialysis access grafts remains a challenging task. Graft surveillance is critical in the prevention of graft thrombosis to prolong graft survival. Once a graft is thrombosed, surgical and percutaneous options are available for restoration of flow. There has been an evolution in the percutaneous treatment of thrombosed dialysis access grafts during the last 20 years, with refinement of pharmacomechanical techniques, allowing for safe and efficacious restoration of flow in thrombosed grafts. There has been emergence of alternative thrombolytic agents to urokinase, which was withdrawn from the United States in late 1998 and recently reintroduced. These alternative thrombolytic agents have similar outcomes compared with urokinase, with the additional advantage of being less expensive. In addition, several mechanical devices, which were popular briefly when urokinase was unavailable, are available currently for use within grafts, with similar success, although their prices have limited widespread use.

KEYWORDS

Grafts - hemodialysis - thrombosis - grafts - thrombolysis - fibrinolytics

REFERENCES

• 1 National Kidney Foundation . Dialysis Outcomes Quality Initiative (NFK-DOQI). Clinical practice guidelines for hemodialysis vascular access.  Am J Kidney Dis. 1997;  30 5154-5196
• 2 National Kidney Foundation . Dialysis Outcomes Quality Initiative (NFK-DOQI). Clinical practice guidelines for hemodialysis vascular access.  Am J Kidney Dis. 2001;  37(suppl 1) s137-s181
• 3 Chazan J A, London M R, Pono L M. Long-term survival of vascular accesses in a large chronic hemodialysis population.  Nephron. 1995;  69 228-233
• 4 Jenkins A M, Buist T A, Glover S D. Medium-term follow-up of forty autogenous vein and forty polytetrafluoroethylene (Gore-Tex) grafts for vascular access.  Surgery. 1980;  88 667-672
• 5 Schwab S J, Raymond J R, Saeed M et al.. Prevention of hemodialysis fistula thrombosis: early detection of venous stenoses.  Kidney Int. 1989;  36 707-711
• 6 Roberts A B, Kahn M B, Bradford S et al.. Graft surveillance and angioplasty prolongs dialysis graft patency.  J Am Coll Surg. 1996;  183 486-492
• 7 Martin L G, MacDonald M J, Kikeri D et al.. Prophylactic angioplasty reduces thrombosis in virgin ePTFE arteriovenous dialysis grafts with greater than 50% stenosis: subset analysis of a prospectively randomized study.  J Vasc Interv Radiol. 1997;  8 163-170
• 8 Pflederer T A, Darras F S, Welch K et al.. How to organize hemodialysis vascular access quality assurance efforts into a cohesive whole for better patient outcomes.  Contemp Dial Nephrol. 2000;  1 18-21
• 9 Bone G E, Pomajzi M J. Management of dialysis fistula thrombosis.  Am J Surg. 1979;  138 901-906
• 10 Brotman D N, Fandos L, Faust G R, Dosher W, Cohen J R. Hemodialysis graft salvage.  J Am Coll Surg. 1994;  178 431-434
• 11 Vesely T M, Idso M C, Audrian J, Windus D W, Lowell J A. Thrombolysis versus surgical thrombectomy for the treatment of dialysis graft thrombosis: pilot study comparing cost.  J Vasc Interv Radiol. 1996;  7 507-512
• 12 Uflacker R, Rajagopalan P R, Vujic I, Stutley J E. Treatment of thrombosed dialysis access grafts: randomized trial of surgical thrombectomy versus mechanical thrombectomy with the Amplatz device.  J Vasc Interv Radiol. 1996;  7 185-192
• 13 Constantinos T S, Cooper S G, Schur I, Patel R I, Iqbal A, Walker S. Retrospective comparison of the Amplatz thrombectomy device with modified pulse-spray thrombolysis in the treatment of thrombosed hemodialysis access grafts.  Radiology. 1999;  213 561-567
• 14 Vesely T M, Williams D, Weiss M et al.. Comparison of the AngioJet rheolytic catheter to surgical thrombectomy for the treatment of thrombosed hemodialysis grafts.  J Vasc Interv Radiol. 1999;  10 1195-1205
• 15 Van Ha T, Kim R. Thrombolysis of dialysis access grafts with the Oasis device versus pulse-spray with rt-PA.  J Vasc Interv Radiol. 2001;  12(suppl) s136-s137
• 16 Casteneda F, Cragg A H, Wyffels P et al.. New thrombolytic brush catheter in thrombosed polytetrafluoroethylene dialysis grafts: Preliminary animal study.  J Vasc Interv Radiol. 1995;  2 10
• 17 Gelbfish G A. Experience with a new suction thrombectomy device in clotted AV grafts.  J Vasc Interv Radiol. 1997;  8 243 (Abst)
• 18 Bucker A, Schmitz-Rode T, Vorwark D, Gunter R. Comparative in vitro study of two percutaneous hydrodynamic thrombectomy systems.  J Vasc Interv Radiol. 1996;  7 445-449
• 19 Trerotola S O, Vesely T M, Lund G B et al.. Treatment of thrombosed hemodialysis access grafts: Arrow-Trerotola percutaneous device versus pulse-spray thrombolysis.  Radiology. 1998;  206 403-414
• 20 Gray R J. Percutaneous intervention for permanent hemodialysis access: a review.  J Vasc Interv Radiol. 1997;  8 313-327
• 21 Schilling J J, Eiser A R, Slifkin R F et al.. The role of thrombolysis in hemodialysis access occlusion.  Am J Kidney Dis. 1987;  10 92-97
• 22 Summers B, Drazen K, Gomes A et al.. Urokinase therapy for thrombosed hemodialysis access grafts.  Surg Gynecol Obstet. 1993;  176 534-538
• 23 Davis G B, Dowd C F, Bookstein J J et al.. Thrombosed dialysis grafts: efficacy of intrathrombic deposition of concentrated urokinase, clot maceration and angioplasty.  AJR Am J Roentgenol. 1989;  149 177-181
• 24 Bookstein J J, Fellmath B, Roberts A et al.. Pulsed-spray pharmacomechanical thrombolysis: preliminary clinical results.  AJR Am J Roentgenol. 1989;  152 1097-1100
• 25 Valji K, Bookstein J J, Roberts A C et al.. Pharmacomechanical thrombolysis and angioplasty in the management of clotted hemodialyis grafts: early and late clinical results.  Radiology. 1991;  178 243-247
• 26 Cynamon J, Lakritz P S, Wahl S I et al.. Hemodialysis graft declottin: description of the “lyse and wait” technique.  J Vasc Interv Radiol. 1997;  8 825-829
• 27 Froehlich J, Stump D L. Recombinant tissue plasminogen activator. In: Camerota AJ Thrombolytic Therapy. Philadelphia, PA; JB Lippincott 1995: 103-114
• 28 Smalling R W. Molecular biology of plasminogen activators: what are the clinical implications of drug design?.  Am J Cardiol. 1996;  19 2-7
• 29 Van Ha T, Santeler S R, Lorenz J L et al.. Thrombolysis of dialysis access grafts: alteplase v. reteplase.  J Vasc Interv Radiol. 2002;  13(suppl) 536-537
• 30 Falk A, Mitty H, Guller J, Teodorescu V, Uribarri J, Vassalotti J. Thrombolysis of clotted hemodialysis grafts with tissue-type plasminogen activator.  J Vasc Interv Radiol. 2001;  12 305-311
• 31 Vogel P, Bansal V, Mashall M. Thrombosed hemodialysis grafts: lyse and wait with tissue plasminogen activator or urokinase compared to mechanical thrombolysis with the Arrow-Trerotola percutaneous thrombolytic device.  J Vasc Interv Radiol. 2001;  12 1157-1165
• 32 Cooper S G. Pulse-spray thrombolysis of thrombosed hemodialysis grafts with tissue plasminogen activator.  AJR Am J Roentgenol. 2003;  180 1063-1066
• 33 Falk A, Guller J, Nowakowski F S et al.. Reteplase in the treatment of thrombosed hemodialysis grafts.  J Vasc Interv Radiol. 2001;  12 1257-1262